Oprozomib
- Generic Name
- Oprozomib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32N4O7S
- CAS Number
- 935888-69-0
- Unique Ingredient Identifier
- MZ37792Y8J
- Background
Oprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS) Malignancies.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT02244112
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT02227914
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Lahey Hospital & Medical Center, Burlington, California, United States
🇺🇸The Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 9
- Registration Number
- NCT02072863
- Locations
- 🇮🇹
Hospital City of Health and Science of Turin, Hematology 1 Division, Turin, Italy
🇮🇹Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy
🇳🇱Erasmus MC, Department of Hematology, Rotterdam, Netherlands
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT01999335
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸James R. Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 22
- Registration Number
- NCT01881789
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Providence St. Joseph's Hospital, Burbank, California, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT01832727
- Locations
- 🇫🇷
CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
🇫🇷CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 210
- Registration Number
- NCT01416428
- Locations
- 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Pacific Cancer Care, Salinas, California, United States
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT01129349
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸Oncology Research Associates, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.